Skip to main content
SpringerLink
Log in

Ethische Probleme in der Schizophrenieforschung

  • Chapter
  • First Online:
Ethik psychiatrischer Forschung

  • 1947 Accesses

Zusammenfassung

Einführend wird auf allgemeine Aspekte relevanter ethischer Problemstellungen der Schizophrenieforschung fokussiert. Hierzu gehören Bedingungsfaktoren mangelnder Einwilligungsfähigkeit und deren standardisierter Beurteilung sowie die Nutzen-Risiko-Analyse aus verschiedenen Perspektiven. Das weit verbreitete Phänomen des „therapeutischen Missverständnisses“, die klinische Behandlung sei zwingend an die Studienteilnahme gekoppelt, wird erläutert. An Beispielen aus den Bereichen Arzneimittelstudien, Psychotherapiestudien und Hirnstimulation werden die ethischen Probleme in der klinischen Forschung bei Schizophrenie illustriert. Zu den für die konkrete Studiendurchführung wichtigen ethischen Aspekten zählen die Definition der Ein- und Ausschlusskriterien sowie der Abbruchkriterien und die kritische Prüfung von placebokontrollierten Studien.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. World Medical Association (2008) Declaration of Helsinki (1964/2008). http://www.wma.net/en/30publications/10policies/b3/17c.pdf. Zugegriffen: 01.10.12

  2. Accornero F, Bini L (1970) An eyewitness account of the discovery of electroshock. Convuls Ther 4: 41-49

    Google Scholar 

  3. Appelbaum P, Grisso T (2001) MacCAT-CR: MacArthur Competence Assessment Tool for Clinical Research. Professional Resource Press, Sarasota, Fla

    Google Scholar 

  4. Appelbaum PS (2006) Decisional capacity of patients with schizophrenia to consent to research: taking stock. Schizophr Bull 32: 22-25

    Article  PubMed  Google Scholar 

  5. Appelbaum PS, Roth LH (1982) Competency to consent to research: a psychiatric overview. Arch Gen Psychiatry 39: 951-958

    Article  PubMed  CAS  Google Scholar 

  6. Brown P (1991) Ethical aspects of drug treatment. In: Bloch S, Chodoff P (Hrsg) Psychiatric ethics, second edition. Oxford University Press, Oxford, S 167-184

    Google Scholar 

  7. Bundesärztekammer (2003) Stellungnahme zur Elektrokrampftherapie. Wiss. Beirat der Bundesärztekammer vom 21.02.2003. Dtsch Ärztebl 100(8): A504/B432/C408

    Google Scholar 

  8. Carpenter WT Jr., Gold JM, Lahti AC, Queern CA, Conley RR, Bartko JJ, Kovnick J, Appelbaum PS (2000) Decisional capacity for informed consent in schizophrenia research. Arch Gen Psychiatry 57: 533-538

    Article  Google Scholar 

  9. Chen DT, Moreno JD (2006) Ethics of medication-free research in schizophrenia. Schizophr Bull 32: 307-309

    Article  PubMed  Google Scholar 

  10. Chong SA, Huxtable R, Campbell A (2011) Authorizing psychiatric research: principles, practices and problems. Bioethics 25: 27-36

    Article  PubMed  Google Scholar 

  11. Deter G, Elsner T (2010) Telematikplattform für Medizinische Forschungsnetze. Wissenschaftliche Dienste Deutscher Bundestag 13, S 1-112

    Google Scholar 

  12. Deutsch E (1996) Das Recht der klinischen Forschung, insbesondere im Bereich der Psychiatrie. Fortschr Neurol Psychiatr 64: 1-7

    Article  PubMed  CAS  Google Scholar 

  13. DGPPN (2006) Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde: Behandlungsleitlinie Schizophrenie. Steinkopf, Darmstadt

    Google Scholar 

  14. Dickerson FB, Lehman AF (2011) Evidence-based psychotherapy for schizophrenia: 2011 update. J Nerv Ment Dis 199: 520-526

    Article  PubMed  Google Scholar 

  15. Dlabac-de Lange JJ, Knegtering R, Aleman A (2010) Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. J Clin Psychiatry 71: 411-418

    Article  PubMed  Google Scholar 

  16. Dunn LB (2006) Capacity to consent to research in schizophrenia: the expanding evidence base. Behav Sci Law 24: 431-445

    Article  PubMed  Google Scholar 

  17. Dunn LB, Candilis PJ, Roberts LW (2006) Emerging empirical evidence on the ethics of schizophrenia research. Schizophr Bull 32: 47-68

    Article  PubMed  Google Scholar 

  18. Dunn LB, Kim DS, Fellows IE, Palmer BW (2009) Worth the risk? Relationship of incentives to risk and benefit perceptions and willingness to participate in schizophrenia research. Schizophr Bull 35: 730-737

    Google Scholar 

  19. Dunn LB, Nowrangi MA, Palmer BW, Jeste DV, Saks ER (2006) Assessing decisional capacity for clinical research or treatment: a review of instruments. Am J Psychiatry 163: 1323-1334

    Article  PubMed  Google Scholar 

  20. Dunn LB, Palmer BW, Keehan M, Jeste DV, Appelbaum PS (2006) Assessment of therapeutic misconception in older schizophrenia patients with a brief instrument. Am J Psychiatry 163: 500-506

    Article  PubMed  Google Scholar 

  21. Freitas C, Fregni F, Pascual-Leone A (2009) Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr Res 108: 11-24

    Article  PubMed  Google Scholar 

  22. Hausner H, Cording C, Hajak G, Spießl H (2008) Aufklärung und Einwilligung in Psychiatrie und Psychotherapie. Psychiat Prax 35: 163-169

    Article  Google Scholar 

  23. Helmchen H (2012) Ethics of clinical research with mentally ill persons. Eur Arch Psychiatry Clin Neurosci 262: 441-452

    Article  PubMed  Google Scholar 

  24. Helmchen H (1998) Ethische Implikationen von Psychotherapie. Nervenarzt 69: 78-80

    Article  PubMed  CAS  Google Scholar 

  25. Hoffmann SO, Rudolf G, Strauß B (2008) Unerwünschte und schädliche Wirkungen von Psychotherapie. Eine Übersicht mit dem Entwurf eines eigenen Modells. Psychotherapeut 53: 4-16

    Article  Google Scholar 

  26. Jakovljevic M (2009) New generation vs. first generation antipsychotics debate: pragmatic clinical trials and practice-based evidence. Psychiatr Danub 21: 446-452

    PubMed  Google Scholar 

  27. Jeste DV, Depp CA, Palmer BW (2006) Magnitude of impairment in decisional capacity in people with schizophrenia compared to normal subjects: an overview. Schizophr Bull 32: 121-128

    Article  PubMed  Google Scholar 

  28. Jeste DV, Palmer BW, Golshan S, Eyler LT, Dunn LB, Meeks T, Glorioso D, Fellows I, Kraemer H, Appelbaum PS (2009) Multimedia consent for research in people with schizophrenia and normal subjects: a randomized controlled trial. Schizophr Bull 35: 719-729

    Article  PubMed  Google Scholar 

  29. Kaup AR, Dunn LB, Saks ER, Jeste DV, Palmer BW (2011) Decisional capacity and consent for schizophrenia research. IRB 33: 1-9

    PubMed  Google Scholar 

  30. Kim SY (2006) When does decisional impairment become decisional incompetence? Ethical and methodological issues in capacity research in schizophrenia. Schizophr Bull 32: 92-97

    Article  Google Scholar 

  31. Kim SY, Appelbaum PS, Swan J, Stroup TS, McEvoy JP, Goff DC, Jeste DV, Lamberti JS, Leibovici A, Caine ED (2007) Determining when impairment constitutes incapacity for informed consent in schizophrenia research. Br J Psychiatry 191: 38-43

    Article  PubMed  Google Scholar 

  32. Klingberg S, Herrlich J, Wiedemann G, Wölwer W, Meisner C, Engel C, Jakobi-Malterre UE, Buchkremer G, Wittorf A (2012) Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study. J Nerv Ment Dis 200: 569-576

    Article  PubMed  Google Scholar 

  33. Klingberg S, Wittorf A (2012) Evidenzbasierte Psychotherapie bei schizophrenen Psychosen. Nervenarzt 83: 907-918

    Article  PubMed  CAS  Google Scholar 

  34. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223

    Article  PubMed  CAS  Google Scholar 

  35. Linden M (2011) Nebenwirkungen und Nebenwirkungserfassung in der Verhaltenstherapie. In: Linden M, Hautzinger M (Hrsg) Verhaltenstherapiemanual. Springer, Heidelberg

    Chapter  Google Scholar 

  36. McMahon RP, Kelly DL, Boggs DL, Li L, Hu Q, Davis JM, Carpenter WT, Jr. (2008) Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research. Schizophr Bull 34: 292-301

    Article  PubMed  Google Scholar 

  37. Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F, Holland R (2004) An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials 25: 598-612

    Article  PubMed  Google Scholar 

  38. Moser DJ, Reese RL, Hey CT, Schultz SK, Arndt S, Beglinger LJ, Duff KM, Andreasen NC (2006) Using a brief intervention to improve decisional capacity in schizophrenia research. Schizophr Bull 32: 116-120

    Article  PubMed  Google Scholar 

  39. Müller-Hegen M (2005) Die Haftung für Aufklärungsfehler im Arztrecht. Dissertation, Mainz

    Google Scholar 

  40. Mulsow JJ, Feeley TM, Tierney S (2012) Beyond consent – improving understanding in surgical patients. Am J Surg 203: 112-120

    Article  PubMed  Google Scholar 

  41. NICE (2010) National Institute for Health & Clinical Excellence: Schizophrenia. The Nice guidelines on core interventions and management of schizophrenia in adults in primary and secondary care. The British Psychological Society and The Royal College of Psychiatrists, London

    Google Scholar 

  42. O'Leary KD, Borkovec TD (1978) Conceptual, methodological, and ethical problems of placebo groups in psychotherapy research. Am Psychol 33:821-830

    Article  PubMed  Google Scholar 

  43. Palmer BW, Jeste DV (2006) Relationship of individual cognitive abilities to specific components of decisional capacity among middle-aged and older patients with schizophrenia. Schizophr Bull 32: 98-106

    Article  PubMed  Google Scholar 

  44. Reimer C (2010) Die Bedeutung der Ethik in der Psychotherapie. In: Arolt V, Kersting A (Hrsg) Psychotherapie in der Psychiatrie: Welche Störung behandelt man wie? Springer, Berlin, S 577-584

    Chapter  Google Scholar 

  45. Riedel M, Leucht S, Rüther E, Schmauss M, Möller HJ (2012) Critical trial-related criteria in acute schizophrenia studies. Eur Arch Psychiatry Clin Neurosci 262: 151-155

    Article  PubMed  Google Scholar 

  46. Roberts LW, Warner TD, Brody JL (2000) Perspectives of patients with schizophrenia and psychiatrists regarding ethically important aspects of research participation. Am J Psychiatry 157: 67-74

    PubMed  CAS  Google Scholar 

  47. Roberts LW, Warner TD, Hammond KG, Hoop JG (2006) Views of people with schizophrenia regarding aspects of research: study size and funding sources. Schizophr Bull 32: 107-115

    Article  PubMed  Google Scholar 

  48. Roberts LW, Warner TD, Nguyen KP, Geppert CM, Rogers MK, Roberts BB (2003) Schizophrenia patients' and psychiatrists' perspectives on ethical aspects of symptom re-emergence during psychopharmacological research participation. Psychopharmacology (Berl) 171: 58-67

    Article  CAS  Google Scholar 

  49. Rossi S, Hallett M, Rossini PM, Pascual-Leone A (2009) The safety of TMS consensus group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 120: 2008-2039

    Article  PubMed  Google Scholar 

  50. Schildmann J, Bauer A, Tilmann A, Vollmann J (2003) Aufklärung und Einwilligung zur Psychopharmakotherapie aus Sicht schizophrener und depressiver Patienten. Eine empirische Untersuchung aus der klinischen Medizinethik. Fortschr Neurol Psychiatr 71: 265-270

    Article  PubMed  CAS  Google Scholar 

  51. Schläpfer TE, Kayser S (2012) Hirnstimulationsverfahren. Transkranielle Magnetstimulation, Magnetkrampftherapie und tiefe Hirnstimulation. Nervenarzt 83: 95-103

    Article  PubMed  Google Scholar 

  52. Shore D (2006) Ethical issues in schizophrenia research: a commentary on some current concerns. Schizophr Bull 32:26-29

    Article  PubMed  Google Scholar 

  53. Sismondo S (2008) Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials 29: 109-113

    Article  PubMed  Google Scholar 

  54. Strauß B, Linden M, Haupt M-L, Kaczmarek S (2012) Unerwünschte Wirkungen, Nebenwirkungen und Fehlentwicklungen. Systematik und Häufigkeit in der Psychiatrie. Psychotherapeut, S 1-9. doi: 101007/s00278-012-0932-x

    Google Scholar 

  55. Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, Kim S, Keefe R, Manschreck T, McEvoy J, Lieberman J (2005) Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophr Res 80: 1-8

    Article  PubMed  Google Scholar 

  56. Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, Kim SY, Manschreck TC, Boshes RA, McEvoy JP, Lieberman JA (2011) Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophr Res 130: 47-52

    Article  PubMed  Google Scholar 

  57. Tandon R (2012) Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry 72 (Suppl. 1): 4-8

    Google Scholar 

  58. Taylor PJ, Awenat Y, Gooding P, Johnson J, Pratt D, Wood A, Tarrier N (2010) The subjective experience of participation in schizophrenia research: a practical and ethical issue. J Nerv Ment Dis 198: 343-348

    Article  PubMed  Google Scholar 

  59. Vollmann J, Bauer A, Danker-Hopfe H, Helmchen H (2003) Competence of mentally ill patients: a comparative empirical study. Psychol Med 33: 1463-1471

    Article  PubMed  CAS  Google Scholar 

  60. Wagner W (1991) Ethische Grundlagen und Probleme der klinischen Psychopharmakologie. In: Pöldinger W, Wagner W (Hrsg) Ethik in der Psychiatrie. Wertebegründung, Wertedurchsetzung. Springer Berlin, S 175-189

    Chapter  Google Scholar 

  61. Wagner W (1990) Placebo. Ethische Prinzipien der kontrollierten Doppelblindprüfung. Ethik Med 2: 68-78

    Google Scholar 

  62. Warner TD, Roberts LW, Nguyen K (2003) Do psychiatrists understand research-related experiences, attitudes, and motivations of schizophrenia study participants? Compr Psychiatry 44: 227-233

    Article  PubMed  Google Scholar 

  63. Wong JC, Bernstein M (2011) Payment of research subjects for more than minimal risk trials is unethical. Am J Med Sci 342: 294-296

    Article  PubMed  Google Scholar 

  64. Wykes T, Steel C, Everitt B, Tarrier N (2008) Cognitive behavior therapy for schizophrenia: Effect sizes, clinical models, and methodological rigor. Schizophr Bull 34: 523-537

    Article  PubMed  Google Scholar 

  65. Yanos PT, Stanley BS, Greene CS (2009) Research risk for persons with psychiatric disorders: a decisional framework to meet the ethical challenge. Psychiatr Serv 60: 374-383

    Article  PubMed  Google Scholar 

  66. Bundespsychotherapeutenkammer Musterberufsordnung. http://www.bptk.de/uploads/media/20060117_musterberufsordnung.pdf. Zugegriffen: 01.10.12

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Psychiatrie und Psychotherapie, LVR-Klinikum Düsseldorf, Kliniken der Heinrich-Heine-Universität Düsseldorf, Bergische Landstr. 2, 40629, Düsseldorf, Deutschland

    Joachim Cordes, Wolfgang Wölwer, Agnes Lowe & Wolfgang Gaebel

Authors
  1. Joachim Cordes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Wölwer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Agnes Lowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wolfgang Gaebel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joachim Cordes .

Editor information

Editors and Affiliations

  1. Charité Campus Benjamin Franklin, Klinik für Psychiatrie/ Psychotherapie, Universitätsmedizin Berlin, Eschenallee 3, Berlin, 14050, Berlin, Germany

    Hanfried Helmchen

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Cordes, J., Wölwer, W., Lowe, A., Gaebel, W. (2013). Ethische Probleme in der Schizophrenieforschung. In: Helmchen, H. (eds) Ethik psychiatrischer Forschung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35055-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-35055-9_13

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-35054-2

  • Online ISBN: 978-3-642-35055-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation